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Abstract
Diffusion basis spectrum imaging (DBSI) combines discrete anisotropic diffusion tensors and the spectrum of isotropic diffusion tensors to model the
underlying multiple sclerosis (MS) pathologies. We used clinical MS subtypes
as a surrogate of underlying pathologies to assess DBSI as a biomarker of
pathology in 55 individuals with MS. Restricted isotropic fraction (reflecting
cellularity) and fiber fraction (representing apparent axonal density) were the
most important DBSI metrics to classify MS using brain white matter lesions.
These DBSI metrics outperformed lesion volume. When analyzing the normalappearing corpus callosum, the most significant DBSI metrics were fiber fraction, radial diffusivity (reflecting myelination), and nonrestricted isotropic fraction (representing edema). This study provides preliminary evidence supporting
the ability of DBSI as a potential noninvasive biomarker of MS neuropathology.

Annals of Clinical and Translational
Neurology 2019; 6(11): 2323–2327
doi: 10.1002/acn3.50903

Introduction
Multiple sclerosis (MS) is a disease with profound heterogeneity clinically, radiologically, and pathologically. Current clinical subtypes of MS do not fully capture its
pathological heterogeneity. Identifying pathologically
meaningful subtypes of MS are crucial in tailoring
immunotherapies and moving toward a personalized
medicine approach in the care of people with MS
(PwMS).1
Diffusion basis spectrum imaging (DBSI) models diffusion-weighted MRI signals as a combination of discrete
anisotropic diffusion tensors (reflecting the axon and
myelin integrity of fibers), and a spectrum of isotropic
diffusion tensors (detecting inflammation and tissue loss
surrounding axons).2 The accuracy of DBSI in capturing
and quantifying white matter (WM) pathologies has been

shown in tissue phantoms, spinal cord, and optic nerves
of mice with experimental allergic encephalomyelitis, the
corpus callosum (CC) of mice with cuprizone-induced
demyelination, autopsied human MS spinal cord, and in
biopsied human brain tissue.3–7
Here, we assessed the ability of DBSI to provide pathologically meaningful differentiation of MS subtypes in living PwMS.

Methods
This cross-sectional study included 55 PwMS (according to
2010 Revised McDonald Criteria)8 from John L. Trotter
MS Center at Washington University in St. Louis. MS clinical subtypes were confirmed by two MS neurologists independently and included relapsing-remitting MS (RRMS),
secondary-progressive MS (SPMS), and primary-
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progressive MS (PPMS). We used the consensus definition
of SPMS which indicates that “in most clinical contexts,
SPMS is diagnosed retrospectively by a history of gradual
worsening after an initial relapsing disease course, with or
without acute exacerbations during the progressive course”.9
Patients underwent detailed clinical assessment, and structural and diffusion imaging. Diffusion data were collected
using a 3 Tesla TIM Trio (Siemens) scanner with a 32channel head coil at 2 9 2 9 2 mm3 resolution in the
axial plane with repetition time/echo time = 10,000/
120 msec, and employing a 99-direction diffusion-weighting scheme (maximum b-value = 1500 sec/mm2).
Voxel-wise DBSI metrics were calculated for two sets of
regions of interest (ROIs) in each PwMS, one consisting of
all brain WM lesions, and the other ROI was the normalappearing CC (excluding lesions in the CC). Normal-appearing WM often harbors pathology in MS, and the CC
was chosen for study due to its large size and ease of identification, axonal coherence, and predilection to be affected
in MS. WM lesion ROIs for the whole brain were created
on fluid-attenuated inversion recovery (FLAIR) images by
automatic segmentation using the Lesion Prediction Algorithm implemented in Lesion Segmentation Tool of Statistical Parametric Mapping (SPM) toolbox in MATLAB.10
To create the ROIs for normal-appearing CC, we first
traced CC on high-resolution magnetization-prepared
rapid acquisition with gradient echo (MP-RAGE) images
using semiautomatic thresholding in Amira 6.0.1. These
CC traces were eroded by one voxel to reduce partial volume effects. SPM-detected lesions within CC were excluded
to obtain normal-appearing CC ROIs.
For analysis, we applied recursive partitioning,11 a nonparametric decision tree-based regression and classification
method, to use DBSI metrics to classify PwMS. Recursive
partitioning involves constructing a decision tree by dividing a dataset into subsets according to descriptors, or rules
that discriminate between different subsets while trying to
maximize the homogeneity within subsequent subsets. In
other words, as the splits occur, the nodes become more
homogeneous. The median values for the following DBSIderived metrics were included in the recursive partitioning:
I Anisotropic components:
a Radial diffusivity (representing myelin integrity of
residual axons)
b Axial diffusivity (representing residual axon integrity)
c Fiber fraction (representing apparent axonal density)
II Isotropic components:
a Restricted fraction (reflecting cellularity)
b Nonrestricted fraction (reflecting extra-axonal environment associated with tissue loss, inflammation, and
cerebrospinal fluid partial volume).
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We also included T2-weighted lesion volume (standardized using median absolute deviation) in the recursive partitioning of WM lesion ROIs.
The Institutional Review Board at Washington University approved the study.

Results
Of the 55 subjects in the study (22 RRMS, 16 SPMS, and
17 PPMS), females comprised a larger proportion among
all subtypes as expected (Table 1). RRMS patients were
on average approximately 14 and 11 years younger than
SPMS and PPMS patients, respectively. Despite a shorter
disease duration, PPMS subjects had similar median
expanded disability status scale (EDSS) score (6) to those
with SPMS.
Figure 1A shows the recursive partitioning tree using
DBSI metrics for brain WM lesions. The most significant
splits were based on DBSI-derived restricted isotropic
fraction and fiber fraction. RRMS subtype was predicted
by relatively higher values for both restricted isotropic
fraction and fiber fraction. Four final classes (terminal
nodes) were identified, with two predicted to contain
individuals with PPMS, one predicted to contain RRMS,
and one predicted as SPMS. Of the nine subjects predicted to have SPMS, seven also had SPMS as a clinical
designation. Figure 1B shows the confusion matrix of the
classifier using DBSI metrics of WM lesions versus predefined clinical subtypes. Based on DBSI metrics of WM
lesions, 35 PwMS (64%) were predicted to have the same
subtype as their predefined clinical subtypes. Notably,
WM lesion volume, as well as other DBSI-derived metrics, did not improve the classification.
Recursive partitioning using DBSI metrics of normal-appearing CC showed that the most significant (first and second) splits were based on DBSI-derived fiber fraction
(Fig. 1C). At the top split, lower fiber fraction (consistent
with lower axon density) predicted a subgroup of PwMS as
having SPMS. Lower but important splits were based on
nonrestricted fraction and radial diffusivity. Of note, DBSIderived radial diffusivity helped predict SPMS versus
RRMS. Those with higher radial diffusivity were predicted
as having SPMS versus RRMS (consistent with more severe
demyelination in SPMS). Five final nodes were identified
including two classes predicted as having RRMS, two as
having SPMS, and one as having PPMS. DBSI of normalappearing CC predicted 37 PwMS (67%) to have the same
subtype as their predefined clinical subtypes (Fig. 1D).

Discussion
Prior histopathological studies of relapsing and progressive MS central nervous system (CNS) tissues have
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Table 1. Demographic and clinical characteristics of 55 patients with MS included in the study.
Characteristics
Sex, n (%)
Female
Male
Age (years), mean  SD
Disease duration from symptoms onset (years), mean  SD
Expanded disability status scale score, median (range)
T2 lesion volume (ml), median (interquartile range)
DBSI-derived metrics in brain white matter lesions
Fiber fraction, median (interquartile range)
Isotropic restricted fraction, median (interquartile range)
Isotropic nonrestricted fraction, median (interquartile range)
Radial diffusivity (lm2/msec), median (interquartile range)
Axial diffusivity (lm2/msec), median (interquartile range)
DBSI-derived metrics in normal-appearing corpus callosum
Fiber fraction, median (interquartile range)
Isotropic restricted fraction, median (interquartile range)
Isotropic nonrestricted fraction, median (interquartile range)
Radial diffusivity (lm2/msec), median (interquartile range)
Axial diffusivity (lm2/msec), median (interquartile range)

RRMS(n = 22)

SPMS(n = 16)

PPMS(n = 17)

15 (68)
7 (32)
43.0  10.7
10.4  8.4
3 (1.5–6)
9.5 (4.4–17.9)

13 (81)
3 (19)
56.7  7.5
27.2  11.8
6 (2.5–6.5)
20.2 (6.1–32.7)

12 (71)
5 (29)
54.1  8.2
12.4  5.9
6 (3–7.5)
8.0 (5.2–14.2)

0.40
0.07
0.43
0.70
1.84

(0.38–0.42)
(0.07–0.08)
(0.40–0.47)
(0.65–0.74)
(1.74–1.97)

0.39
0.06
0.46
0.68
1.92

(0.37–0.47)
(0.04–0.07)
(0.39–0.50)
(0.64–0.71)
(1.83–2.02)

0.37
0.07
0.48
0.70
1.99

(0.32–0.41)
(0.05–0.08)
(0.43–0.53)
(0.66–0.74)
(1.79–2.11)

0.61
0.19
0.04
0.31
2.25

(0.58–0.66)
(0.18–0.21)
(0.00–0.10)
(0.20–0.35)
(2.12–2.36)

0.60
0.16
0.04
0.30
2.13

(0.54–0.68)
(0.12–0.19)
(0.02–0.15)
(0.20–0.34)
(2.02–2.24)

0.61
0.20
0.05
0.33
2.11

(0.58–0.66)
(0.17–0.23)
(0.03–0.07)
(0.29–0.38)
(2.06–2.25)

RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; PPMS, primary-progressive multiple sclerosis; DBSI, diffusion basis spectrum imaging.

described pathological heterogeneity.12,13 However, CNS
tissue cannot be accessed easily and safely in living PwMS.
A major goal of this study was to use the relative pathological differences among MS clinical subtypes, based on
published studies of neuropathology, to investigate the
ability of DBSI as a noninvasive imaging method to differentiate components of MS pathology, and to determine
which DBSI metrics were most important in this regard.
We previously showed in preclinical models, and autopsied and biopsied human tissue that DBSI restricted isotropic fraction correlated significantly and positively with
cellularity, and fiber fraction had a significant positive correlation with axonal density.2,3,5,7 The current study suggests that DBSI may be useful in living individuals with
MS. The clinical subtypes of 64% and 67% of PwMS in our
study were predicted by recursive partitioning of DBSIderived metrics of WM lesions and of normal-appearing
CC, respectively. It is noteworthy that our recursive partitioning was solely based on DBSI metrics and did not
include any demographic or clinical metrics such as age,
gender, disease duration, and EDSS, all of which may contribute to differentiating MS subtypes clinically.
We found that restricted isotropic fraction and fiber fraction of WM lesions were the most important DBSI metrics
when using brain WM lesions to predict MS clinical subtypes. It is noteworthy that DBSI metrics performed better
than T2-weighted lesion volume at discerning clinical subtypes in our study, although prior studies have often

reported higher T2 lesion loads to be associated with SPMS
versus RRMS. Out of 22 subjects designated as RRMS clinically, 15 were predicted to have RRMS by DBSI metrics, 6
were predicted to have PPMS and only one was predicted
to have SPMS. These results suggest that RRMS WM
lesions in our subjects were more similar to PPMS than
SPMS in terms of axon density and cellularity.
When analyzing DBSI metrics of normal-appearing CC,
the most significant factor to predict MS subtype was
fiber fraction, with radial diffusivity and nonrestricted isotropic fraction also of importance. Based on the known
pathology of SPMS, it was not unexpected that those predicted to be SPMS had the lowest fiber fractions (representing apparent axonal density) within normal-appearing
CC.14 Compared to RRMS, SPMS was also predicted by
greater apparent demyelination based on higher DBSIderived radial diffusivity, also not unexpected.15 A higher
nonrestricted isotropic fraction in normal-appearing CC
predicted RRMS over PPMS. This is possibly due to more
edema in the RRMS group, about 15% of whom had
gadolinium-enhancing brain lesions (albeit not all in the
CC). In contrast, only 7% of PPMS and none of the
SPMS subjects given gadolinium displayed an enhancing
brain lesion.
Our study has some limitations. First, we base our
pathological interpretations of these DBSI findings on
animal and MS autopsy studies without much pathological confirmation in living humans with MS. However, we
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(B)

(A)

Recursive partitioning analysis using DBSI metrics of white matter lesions

(D)

(C)

Recursive partitioning analysis using DBSI metrics of normal appearing corpus callosum excluding lesions
Figure 1. Results of recursive partitioning analysis for 55 people with multiple sclerosis using diffusion basis spectrum imaging (DBSI) metrics of
white matter (WM) lesions (A), and normal-appearing corpus callosum excluding lesions (C), and the corresponding confusion matrices ((B) and
(D)). The predictors included in recursive partitioning analysis were DBSI-derived anisotropic components (radial diffusivity, axial diffusivity, and
fiber fraction), isotropic components (restricted fraction, and nonrestricted fraction), and lesion volume (only when analyzing WM lesions). The
most significant splits in recursive partitioning of WM lesions were based on restricted fraction and fiber fraction (A). This suggests that cellularity
and apparent axon density were the most important characteristics (based on DBSI metrics) of WM lesions for predicting clinical subtypes. Using
DBSI metrics of WM lesions, 35 individuals (64%) were predicted to have the same disease subtype as their predefined clinical subtype as shown
in the diagonal of the matrix (B). When analyzing normal-appearing corpus callosum, the most important DBSI-derived characteristics were fiber
fraction followed by nonrestricted isotropic fraction and radial diffusivity (C), with 37 individuals (67%) predicted to have the same disease
subtype as their predefined clinical subtypes (D).

recently showed that findings from DBSI metrics were
consistent with pathology findings in a biopsied inflammatory demyelinating WM brain lesion.7 While the
majority of the MS participants in our study did not have
active disease, we cannot completely rule out if active
inflammation in some might have confounded the findings with our limited sample size. DBSI of the spinal cord
was not a part of the present studies. We are working to
overcome technical challenges in applying DBSI to the
human spinal cord and hope to include it in future studies. Gray matter lesions are particularly common in progressive forms of MS, but DBSI metrics of gray matter
were not included due to the lower image resolution in
diffusion-weighted images. Our study was cross-sectional.
Longitudinal studies, which are underway, will be valuable
to evaluate the meaning of DBSI metrics in relation to
the pathological heterogeneity of MS over time. It would
also be interesting to compare DBSI with other diffusion
models. Last but not the least, our findings need to be
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validated in external independent datasets, including more
subjects with concurrent biopsies.
Overall, this study provides preliminary evidence supporting the ability of DBSI as a potential noninvasive biomarker of MS neuropathology. Future studies are needed
to evaluate the utility of DBSI as a potential outcome
measure in trials of remyelinating and neuroprotective
agents.
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